The Globe and Mail reports in its Friday, April 3, edition that TD Cowen analyst David Kwan rates Healwell AI "buy," with a $1.75 share target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $2.50. Mr. Kwan says Healwell is "well-positioned to benefit from increasing artificial intelligence adoption in healthcare." Mr. Kwan says in a note: "We believe the shares are poised to continue the rebound from their recent 52-week low, as Healwell benefits from its strengthened competitive position with the transformational Orion acquisition and its proven/validated AI and data science platform. We expect increased cross-selling wins to drive stronger organic growth and margin expansion, which should help drive a re-rating." The Globe reported on May 1 that Scotia Capital analyst Kevin Krishnaratne had commenced coverage on Healwell AI with a "sector outperform" ranking. The shares could then be had for $1.48. The Globe reported on Feb. 6 that Ventum Capital analyst Rob Goff had reaffirmed his "buy" rating for Healwell AI. The shares could then be had for 70 cents.